SouthViews No. 209, 30 October 2020
Creative imitation at the front of pharma biotechnology opportunities: some lessons from late late industrialization countries
By Pablo Lavarello and Sebastián Sztulwark
Given that high-cost biopharmaceutical drug patents have started to expire since the early 2000s, biotechnology opens up opportunities for developing countries to pursue an upgrading process by entering the sector as early imitators. Developing these opportunities was transformed on priority needs of health systems since the outbreak of COVID-19. Certain developing countries have advanced in a strategy of imitating biotechnological reference drugs once their patents have expired, opening a possibility for a catching up process.
Download the SouthViews:
This article was tagged: Access to Medicines, Biosimilars, Biotechnological Products, COVID-19, Creative Imitation, Generic Medicines, Health Systems, India, Innovation, Intellectual Property, Korea, Patent, Pharmaceuticals, Research and Development (R&D)
